Summary
The administration of 14 daily doses of cyproheptadine, BC-105, metergoline and methysergide induced a marked decrease in the number (B max) of 3H-spiroperidol binding sites (5HT2 sites) in frontal cortex, when assayed 48 h after the last dose; the apparent affinity (K D) of 3H-spiroperidol was not changed. The same treatment schedules failed to modify the K D and B max values for 3H-5HT binding to the 5HT1 site in the hippocampus. Cyproheptadine, BC-105 and methysergide, but not metergoline, decreased the density of 5HT2 sites in frontal cortex 48 h after a single dose. Additional studies of the decrease in 3H-spiroperidol binding after in vivo treatment with cyproheptadine showed that the extent of binding loss was unaltered by repeated washing. Furthermore, cyproheptadine added in vitro to membranes isolated from frontal cortex inhibited the binding of 3H-spiroperidol in a competitive manner; Scatchard plots were linear with the same maximum binding (B max) and different slopes. Therefore, these preliminary studies suggest that the loss of 5HT2 binding sites after in vivo treatment with cyproheptadine and with other 5HT antagonists may reflect an adaptive response. This apparent paradoxical effect suggests that the action of these drugs at the 5HT2 binding sites should be reevaluated.
Similar content being viewed by others
References
Blackshear MA, Steranka LR, Sanders-Bush E (1981) Multiple serotonin receptors: Regional distribution and effect of raphe lesions. Eur J Pharmacol 76:325–334
Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308
Creese I, Snyder S (1978) 3H-spiroperidollabels serotonin receptors in rat cerebral cortex and hippocampus. Eur J Pharmacol 49:201–208
Creese I, Sibley DR (1981) Receptor adaptation to centrally acting drugs. Ann Rev Pharmacol 21:357–391
Deakin JFW, Green AR (1978) The effects of putative 5-hydroxytryptamine antagonists on the behavior produced by administration of tranylcypromine and l-tryptophan or tranylcypromine and l-dopa to rats. Br J Pharmac 64:201–209
Fillion G, Rouselle JC, Beaudoin D, Pradelles P, Goiny M, Dray F, Jacob J (1979) Serotonin sensitive adenylate cyclase in horse brain synaptosomal membranes. Life Sci 24:1813–1822
Fozard JR (1975) The animal pharmacology of drugs used in the treatment of migraine. J Pharm Pharmacol 27:297–321
Fuxe K, Ogren SO, Agnati L, Gustafsson JA, Jonsson G (1977) On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neurosci Lett 6:339–343
Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. I. The disposition of 3H-norepinephrine, 3H-dopamine and 3H-dopa in various regions of the brain. J Neurochem 13:655–669
Kellar KJ, Cascio CS, Butler JA, Kurtzke RN (1981) Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain. Eur J Pharmacol 69:515–518
Leysen JE, Gommeren W, Laduron PM (1978a) Spiperone: a ligand of choice for neuroleptic receptors. Mol Pharmacol 27:307–316
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978b) Serotonergic component of neuroleptic receptors. Nature 272:168–171
Leysen JE, Awouters F, Kennis L, Laduron PM, van der Berg J, Janssen PAJ (1981) Receptor binding profile of R 41 468, a novel antagonist of 5 HT2 receptors. Life Sci 28:1015–1022
Leysen JE, Niemegeers CJE, van Nueten JM, Laduron PM (1982) 3H-Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Maj J, Swonska H, Baran L, Ganacarczyk L, Rawlow A (1978) The central antiserotonergic action of mianserin. Psychopharmacology 59:79–84
Maj J, Lewandowska A, Rawlow A (1979) Central antiserotonin action of amitriptyline. Pharmakopsychiatry 12:281–285
Mallot M, Hamon M (1982) Calcium-gaunine nucleotide interactions in brain membranes. I. Modulation of central 5-hydroxytryptamine receptors in the rat. J Neurochem 38:151–161
Nelson DL, Herbet A, Bougoin S, Glowinski J, Hamon M (1978) Characteristics of central 5HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 14:983–995
Ogren SO, Fuxe K, Agnati LF, Gustafsson JA, Jonsson G, Holm AC (1979) Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of the functional activity of central 5HT system by antidepressant drugs. J Neural Transm 46:85–103
Oswald I, Brezinova V, Dunleavey DLF (1972) On the slowness of action of tricyclic antidepressant drugs. Br J Psychiat 120:673–677
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Mol Pharmacol 16:687–699
Peroutka SJ, Snyder SH (1980a) Long-term antidepressant treatment decreases spiroperidol labelled serotonin receptor binding. Science 210:88–90
Peroutka SJ, Snyder SH (1980b) Regulation of serotonin2 (5HT2) receptors labelled with 3H-spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582–587
Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212:827–829
Przegalinski E, Leokadia B, Wladyslaw P, Siwanowicz J (1979) The central action of pizotifen. Psychopharmacology 62:295–300
Samanin R, Mennini T, Ferraris A, Bendotti C, Barsini F (1980) Hyper-and hyposensitivity of central serotonin receptors: 3H-serotonin binding and functional studies in the rat. Brain Res 189:449–457
Speight TM, Avery GS (1972) Pizotifen (BC-105): A review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drug 3:159–203
van Riezen H (1972) Different central effects of the 5HT antagonists mianserin and cyproheptadine. Arch Int Pharmacodyn 198:256–269
Vargaftig BB, Coignet JL, de Vos CJ, Grilsen H, Bonta JL (1971) Mianserin hydrochloride: Peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine. Eur J Pharmacol 16:336–346
Author information
Authors and Affiliations
Additional information
These investigations were supported by U.S. Public Health Service Grants MH 26463 and MH 34007 and the Tennessee Department of Mental Health and Retardation. RLF is a recipient of a Pharmaceutical Manufacturers Association Predoctoral Fellowship
Rights and permissions
About this article
Cite this article
Blackshear, M.A., Friedman, R.L. & Sanders-Bush, E. Acute and chronic effects of serotonin (5HT) antagonists on serotonin binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 324, 125–129 (1983). https://doi.org/10.1007/BF00497017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00497017